Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1402-1416

  Rea, Vincenza Elena Anna ^a   Lavecchia, Antonio ^a   Di Giovanni, Carmen ^a   Rossi, Francesca Wanda ^a   Gorrasi, Anna ^b   Pesapane, Ada ^a   De Paulis, Amato ^a   Ragno, Pia ^b   Montuori, Nunzia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

[1 (PHENANTHREN 9 YL)GUANIDINE]; [4,4' DIMETHYL (1,1' BIPHENYL) 2,2',5,5' TETRAOL]; [8 [[4 (TERT BUTYL) PHENOXY]METHYL] 1,3 DIMETHYL 1H PURINE 2,6(3H,9H)DIONE]; [PIPERIDIN 2 YL[2 (TRIFLUOROMETHYL) 6 [(4 TRIFLUOROMETHYL)PHENYL]PYRIDIN 4 YL]METHANOL]; ANTINEOPLASTIC AGENT; FIBRONECTIN; INTEGRIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VITRONECTIN;

ARTICLE; BINDING AFFINITY; BIOTINYLATION; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CELL STRUCTURE; CHEMOTAXIS; DRUG BINDING SITE; EXTRACELLULAR MATRIX; FETAL CALF SERUM; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR SIGNALING; IONIZATION; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; TAUTOMER;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL ADHESION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASM INVASIVENESS; NEOPLASMS; PROTEIN BINDING; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; VITRONECTIN;

EID: 84882287352     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1249     Document Type: Article

References (52)

1. Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-43.
2. Ragno P. The urokinase receptor: A ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci 2006;63:1028-37.
3. Llinas P, Le Du MH, Gardsvoll H, Danø K, Ploug M, Gilquin B, et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005;24:1655-63.
4. Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, et al. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol 2006;363:482-95.
5. Montuori N, Cosimato V, Rinaldi L, Rea VE, Alfano D, Ragno P. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors. Thromb Haemost 2013;109:309-18.
6. Montuori N, Ragno P. Multiple activities of a multifaceted receptor: Roles of cleaved and soluble uPAR. Front Biosci 2009;14: 2494-503.
7. Van der Pluijm G, Sijmons B, Vloedgraven H, van der Bent C, Drijfhout JW, Verheijen J, et al. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 2001;159:971-82.
8. Tang CH, Wei Y. The urokinase receptor and integrins in cancer progression. Cell Mol Life Sci 2008;65:1916-32.
9. Degryse B, Resnati M, Czekay RP, Loskutoff DJ, Blasi F. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: Generation of a new integrin inhibitor. J Biol Chem 2005;280:24792-803.
10. Chaurasia P, Aguirre-Ghiso JA, Liang OD, Gardsvoll H, Ploug M, Ossowski L. A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. J Biol Chem 2006;281:14852-63.
11. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002;1:445-57.
12. Jo M, Thomas KS, Marozkina N, Amin TJ, Silva CM, Parsons SJ, et al. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J Biol Chem 2005;280:17449-57.
13. Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol 2002;23:541-8.
14. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002;277:46932-9.
15. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, et al. The fibrinolytic receptor for urokinase activates the G proteincoupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A 2002;99:1359-64.
16. de Paulis A, Montuori N, Prevete N, Fiorentino I, Rossi FW, Visconte V, et al. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and-like 2. J Immunol 2004;173: 5739-48.
17. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-8.
18. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: Vitronectin provides the key. J Cell Biol 2007;177:927-39.
19. Sidenius N, Andolfo A, Fesce R, Blasi F. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J Biol Chem 2002;277:27982-90.
20. Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, et al. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 1999;59:5307-14.
21. Degryse B, Orlando S, Resnati M, Rabbani SA, Blasi F. Urokinase/urokinase receptor and vitronectin/alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 2001;20:2032-43.
22. Gargiulo L, Longanesi-Cattani I, Bifulco K, Franco P, Raiola R, Campiglia P, et al. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J Biol Chem 2005;280:25225-32.
23. Jo M, Takimoto S, Montel V, Gonias SL. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice. Am J Pathol 2009;175:190-200.
24. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. uPAR induces epithelialmesenchymal transition in hypoxic breast cancer cells. J Cell Biol 2007;178:425-36.
25. Madsen CD, Sidenius N. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol 2008; 87:617-29.
26. Gardsvoll H, Ploug M. Mapping of the vitronectin-binding site on the urokinase receptor: Involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J Biol Chem 2007;282:13561-72.
27. Huai Q, Zhou A, Lin L, Mazar AP, Parry GC, Callahan J, et al. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol 2008;15:422-3.
28. Lyne PD. Structure-based virtual screening: An overview. Drug Discov Today 2002;7:1047-55.
29. DeLano WL. The PyMOL molecular graphics system on worldwide web. 2005. Available from: Http://www.pymol.org.
30. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000;28:235-42.
31. Available from: Http://dtp.nci.nih.gov/branches/dscb/diversity- explanation.html.
32. Available from: Http://dtp.cancer.gov.
33. Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: Implications for tumor progression and therapy. Clin Cancer Res 2008;14:5649-55.
34. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47: 1739-49.
35. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47: 1750-9.
36. Jacobsson M, Garedal M, Schultz J, Karlen A. Identification of Plasmodium falciparum spermidine synthase active site binders through structure-based virtual screening. J Med Chem 2008;51:2777-86.
37. Høyer-Hansen G, Pessara U, Holm A, Pass J, Weidle U, Danø K, et al. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J 2001;358:673-9.
38. Bodary SC, McLean JW. The integrin beta 1 subunit associates with the vitronectin receptor alpha v subunit to form a novel vitronectin receptor in a human embryonic kidney cell line. J Biol Chem 1990; 265:5938-41.
39. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22: 3099-108.
40. Dunitz JD, Taylor R. Organic fluorine hardly ever accepts hydrogen bonds. Chem Eur J 1997;3:89.
41. Dunitz JD. Organic fluorine: Odd man out. Chem Biol Chem 2004;5: 614-21.
42. Carriero MV, Longanesi-Cattani I, Bifulco K, Maglio O, Lista L, Barbieri A, et al. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther 2009;8:2708-17
43. Bifulco K, Longanesi-Cattani I, Franco P, Pavone V, Mugione P, Di Carluccio G, et al. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion. PLoS ONE 2012;7:e44806.
44. Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): An essential player in multiple games of cancer: A review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006;5: 1760-71.
45. Kjoller L, Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol 2001;152:1145-57.
46. Decock J, Thirkettle S, Wagstaff L, Edwards DR. Matrix metalloproteinases: Protective roles in cancer. J Cell Mol Med 2011;15:1254-65.
47. Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, et al. Virtual screening targeting the urokinase receptor, biochemical and cellbased studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. J Med Chem 2011;54:7193-205.
48. Wang F, Eric Knabe W, Li L, Jo I, Mani T, Roehm H, et al. Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. Bioorg Med Chem 2012;20:4760-73.
49. Preissner KT, Reuning U. Vitronectin in vascular context: Facets of a multitalented matricellular protein. Semin Thromb Hemost 2011;37: 408-24.
50. Lavecchia A, Di Giovanni C, Pesapane A, Montuori N, Ragno P, Martucci NM, et al. Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening. J Med Chem 2012;55:4142-58.
51. Lo Conte L, Chothia C, Janin J. The atomic structure of protein-protein recognition sites. J Mol Biol 1999;285:2177-98.
52. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat Rev Drug Discov 2004; 3:301-17.